NASDAQ:TELO
READ THE FULL TELO RESEARCH REPORT
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”
The company just released potential groundbreaking results from a preclinical study of Telomir-1 on human cell lines. Data from the test showed the ability of Telomir-1 to “fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provided robust cellular protection against copper toxicity.”
Oxidative stress occurs when there is an imbalance between free radicals (ROS) and antioxidants in the body, leading to cellular damage. Free radicals are unstable molecules that can harm proteins, DNA, and cell membranes, while antioxidants help neutralize them. This imbalance can contribute to aging and is implicated in the development of various diseases. Oxidative stress plays a key role in chronic conditions such as cardiovascular diseases (e.g., atherosclerosis and hypertension), neurodegenerative disorders (e.g., Alzheimer’s disease and Parkinson’s disease), diabetes, cancer, and inflammatory diseases like rheumatoid arthritis. It is also linked to complications in conditions like chronic obstructive pulmonary disease (COPD) and kidney disease.
Telomir is evaluating Telomir-1 for the treatment of viral infections as well, such as avian influenza, otherwise known as bird flu, where oxidate stress is a key factor in disease severity. Viral infections trigger and exploit excessive ROS production as a mode to facilitate their replication, leading to widespread inflammation, cellular damage, and impaired immune responses. This oxidative damage exacerbates disease progression and increases the risk of severe outcomes
According to the company, there are currently no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1’s ability to reverse oxidative stress and protect cells offers a promising avenue for addressing this gap. By mitigating the cellular damage associated with oxidative stress, Telomir-1 has the potential to play a critical role in reducing the severity of such infections.
This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions.
It’s this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. We urge investors who have a higher risk tolerance to take a look at TELO and consider investing in a company at an early stage that has a large potential upside, with a low float and positive news flow likely in the near future, providing potential fuel to the stock.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
